Disorders of glucose metabolism among HIV-infected women

Clinical Infectious Diseases

Volumn 40, Issue 10, 2005, Pages 1492-1499

  Howard, Andrea A ^a,b   Floris Moore, Michelle ^a   Arnsten, Julia H ^a   Santoro, Nanette ^a   Fleischer, Norman ^a   Lo, Yungtai ^a   Schoenbaum, Ellie E ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; METHADONE; PROTEINASE INHIBITOR;

ADULT; AGED; ARTICLE; BODY MASS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; ETHNOLOGY; FAMILY HISTORY; FEMALE; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISPANIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RELEASE; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; METHADONE TREATMENT; ORAL GLUCOSE TOLERANCE TEST; PHYSICAL ACTIVITY; PRIORITY JOURNAL; SMOKING; WAIST CIRCUMFERENCE;

ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DIABETES MELLITUS; FEMALE; GLUCOSE; GLUCOSE TOLERANCE TEST; HIV INFECTIONS; HUMANS; INSULIN; INSULIN RESISTANCE; MIDDLE AGED; ODDS RATIO; RISK FACTORS;

EID: 18244391191     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/429824     Document Type: Article

References (32)

1. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. The HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-60.
2. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353:2093-9.
3. Behrens G, Dejam A, Schmidt H, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999; 13:F63-F70.
4. Mulligan K, Grunfeld C, Tai VW, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000; 23:35-43.
5. Tsiodras S, Mantzoros C, Hammer S, Samore M. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy. Arch Intern Med 2000; 160:2050-6.
6. Justman JE, Benning L, Danoff A, et al. Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr 2003; 32:298-302.
7. Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 2000; 275:20251-4.
8. Murata H, Hruz PW, Mueckler M. Indinavir inhibits the glucose transporter isoform Glut4 at physiologic concentrations. AIDS 2002; 16:859-63.
9. Hadigan C, Meigs JB, Corcoran C, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001; 32:130-9.
10. Dubé MP, Edmondson-Melancon H, Qian D, Aqeel R, Johnson D, Buchanan TA. Prospective evaluation of the effect of initiating indinavir-based therapy on insulin sensitivity and B-cell function in HIV-infected patients. J Acquir Immune Defic Syndr 2001; 27:130-4.
11. Miller SA, Santoro N, Lo Y, et al. Menopause symptoms in HIV-infected and drug-using women. Menopause (in press).
12. Ewing JA. Detecting alcoholism: the CAGE questionnaire. JAMA 1984; 252:1905-7.
13. Mayfield D, McLeod G, Hall P. The CAGE questionnaire: validation of a new alcoholism screening instrument. Am J Psychiatry 1974; 131:1121-3.
14. World Health Organization. Report of a WHO Scientific Working Group: research on the menopause in the 1990s. WHO Technical Report Series 866. Geneva: WHO, 1996.
15. WHO Study Group. Diabetes mellitus. Report of a WHO study group. WHO technical report series 727. Geneva: WHO, 1985:99.
16. American Diabetes Association. Screening for type 2 diabetes. Diabetes Care 2004; 27(Suppl 1):S11-4.
17. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412-9.
18. Phillips DJW, Clark PM, Hales CN, Osmond C. Understanding oral glucose tolerance: comparison of glucose or insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and insulin secretion. Diabet Med 1994; 11:286-92.
19. Sowers M, Derby C, Jannausch ML, Torrens JI, Pasternak R. Insulin resistance, hemostatic factors, and hormone interactions in pre- and perimenopausal women: SWAN. J Clin Endocrinol Metab 2003; 88:4904-10.
20. Noor MA, Lo JC, Mulligan K, et al. Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS 2001; 15:F11-8.
21. Dubé MP, Qian D, Edmondson-Melancon H, et al. Prospective intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy. Clin Infect Dis 2002; 35:475-81.
22. Dubé MP, Zackin R, Parker R, et al. Prospective study of glucose and lipid metabolism in antiretroviral-naive subjects randomized to receive nelfinavir, efavirenz, or both combined with zidovudine + lamivudine or didanosine + stavudine: A5005s, a substudy of ACTG 384 [abstract 74]. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infection (San Francisco). Alexandria, VA: Foundation for Retrovirology and Human Health, 2004:104.
23. Noor MA, Parker RA, O'Mara E, et al. The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. AIDS 2004; 18:2137-44.
24. Pouliot MC, Despres JP, Lemieux S, et al. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol 1994; 73:460-8.
25. Passariello N, Giugliano D, Ceriello A, Chiariello A, Sgambato S, D'Onofrio F. Impaired insulin response to glucose but not to arginine in heroin addicts. J Endocrinol Invest 1986; 9:353-7.
26. Ceriello A, Giugliano D, Passariello N, et al. Impaired glucose metabolism in heroin and methadone users. Horm Metab Res 1987; 19:430-3.
27. Sadava D, Alonso D, Hong H, Pettit-Barrett D. Effect of methadone addiction on glucose metabolism in rats. Gen Pharmacol 1997; 28:27-9.
28. Howard AA, Klein RS, Schoenbaum EE. Association of hepatitis C infection and antiretroviral use with diabetes mellitus in drug users. Clin Infect Dis 2003; 36:1318-23.
29. Mehta SH, Moore RD, Thomas DL, Chaisson RE, Sulkowski MS. The effect of HAART and HCV infection on the development of hyperglycemia among HIV-infected persons. J Acquir Immune Defic Syndr 2003; 33:577-84.
30. Attvall S, Fowelin J, Lager I, Von Schenck H, Smith U. Smoking induces insulin resistance - a potential link with the insulin resistance syndrome. J Intern Med 1993; 233:327-32.
31. Eliasson B, Attvall S, Taskinen MR, Smith U. The insulin resistance syndrome in smokers is related to smoking habits. ArteriosclerThromb 1994; 14:1946-50.
32. Schambelan M, Benson CA, Carr A, et al. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA Panel. J Acquir Immune Defic Syndr 2002; 31:257-75.